Search

Displaying results 2071 - 2080 of 8573 in total
  1. Drug

    Ixabepilone

    go.drugbank.com/drugs/DB04845
    ApprovedInvestigational

    Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. … It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.

  2. Drug

    Doxacurium

    go.drugbank.com/drugs/DB01135
    ApprovedWithdrawn

    Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.

  3. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650] … [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc.

  4. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    [A225751, A225756, A225766, A191829, L27986] Margetuximab binds to the same epitope on the HER2 extracellular domain and induces the same effects as [trastuzumab]. … [A225751, A225756, A225766, A191829, L27986] Margextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA™ by MacroGenics, Inc.[L27986]

  5. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    Dehydrocholic acid is a synthetic bile acid that was prepared from the oxidation of cholic acid with chromic acid [A33022]. It has been used for stimulation of biliary lipid secretion. … The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.

    Products: Dycholium Tablet 300mg
  6. Drug

    Taurochenodeoxycholic acid

    go.drugbank.com/drugs/DB08833
    Experimental

    As a medication, taurochenodeoxycholic acid reduces cholesterol formation in the liver, and is likely used as a choleretic to increase the volume of bile secretion from the liver and as a cholagogue to … Its physiologic function is to emulsify lipids such as cholesterol in the bile.

  7. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … [A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5.

  8. Drug

    Ropeginterferon alfa-2b

    go.drugbank.com/drugs/DB15119
    ApprovedInvestigational

    [A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials. … [A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients.

  9. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. … The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase.

  10. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing … [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]